1 / 6

Chronic Urticaria Or Hives Therapeutic Development Report 20

This report provides comprehensive information on the therapeutic development for Chronic Urticaria Or Hives, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Ctroutman01
Télécharger la présentation

Chronic Urticaria Or Hives Therapeutic Development Report 20

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Chronic Urticaria Or Hives - Pipeline Review, H1 2015 By RnRMarketResearch.com Publisher Name : Global Markets Direct Date: 20-May-2015 No. of pages: 71 Single User License: US $2000 Browse more Reports on Dermatology therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/dermatology-therapeutics ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  2. Chronic Urticaria Or Hives - Pipeline Review, H1 2015 This report gives far reaching data on the restorative advancement for Chronic Urticaria Or Hives, complete with relative investigation at different stages, therapeutics appraisal by medication target, component of activity (MoA), course of organization (RoA) and atom sort, alongside most recent overhauls, and highlighted news and press discharges. It likewise surveys key players included in the remedial advancement for Chronic Urticaria Or Hives and extraordinary elements on late-stage and stopped undertakings. The report improves choice making abilities and help to make compelling counter procedures to increase upper hand. It reinforces R&D pipelines by distinguishing new targets and MOAs to create first-in-class and best-in-class items. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  3. Chronic Urticaria Or Hives - Pipeline Review, H1 2015 Companies Discussed/Mentioned in this Research : AstraZeneca PLC, Biofrontera AG, Bristol-Myers Squibb Company, ELORAC, Inc., F. Hoffmann-La Roche Ltd., FAES Farma SA, Genentech, Inc., GlaxoSmithKline plc, Merck & Co. andPanaceaBiotec Limited. Drugs Profile Discussed in this Research : abatacept (recombinant), AZD-1981, BF-Derm-1, bilastine, cidoxepin hydrochloride, desloratadine, GSK-2646264, JDP-205, omalizumab, omalizumab biosimilar and quilizumab. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  4. Chronic Urticaria Or Hives - Pipeline Review, H1 2015 Scope For Chronic Urticaria Or Hives 2015 • The report provides a snapshot of the global therapeutic landscape of Chronic Urticaria Or Hives • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Chronic Urticaria Or Hives and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Chronic Urticaria Or Hives products under development by companies and universities/research institutes based on information derived from company and industry-specific sources • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  5. Chronic Urticaria Or Hives - Pipeline Review, H1 2015 Reasons to Buy: • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Chronic Urticaria Or Hives • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives pipeline depth and focus of Indication therapeutics ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  6. Chronic Urticaria Or Hives - Pipeline Review, H1 2015 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

More Related